BIOBRIEF
Gladstone Institutes researchers trace APOE4's early effect on memory neurons to a single regulatory brain protein, Nell2, and point to a pre symptomatic intervention window in mice.
A new mouse study from the Gladstone Institutes finds that the APOE4 Alzheimer's risk gene, carried by roughly one in four people, may already be shrinking and over-activating memory neurons decades before any symptom appears. The reversible protein behind the effect, Nell2, is the actual news.
Published in Nature Aging, the work is the first direct, age-dependent look at how APOE4 reshapes neurons in young animals. In mice carrying the variant, APOE4 pushed Nell2 levels up. Neurons in the hippocampus, the brain's memory hub, shrank and fired abnormally fast. Mice with the strongest early hyperactivity went on to develop the worst memory problems later, the team reports.
Crucially, lowering Nell2 in adult mice pushed those neurons back toward a normal size and quieted the over-firing. That reversibility is the constructive hook: if APOE4 is already reshaping circuits before memory slips, the intervention window is pre-symptomatic, not symptomatic.
The lead author, Misha Zilberter, PhD, frames the work as the first direct examination of age-dependent neuronal effects of APOE4. The findings are in mice; human translation is years away at best, and mouse APOE4 studies have a long record of failing to translate into human therapy. For the roughly one in four people who carry APOE4, the practical takeaways are still limited to monitoring and trial enrollment, not a coming treatment.